KR102469995B1 - 헤테로아릴 치환된 피리딘 및 사용 방법 - Google Patents

헤테로아릴 치환된 피리딘 및 사용 방법 Download PDF

Info

Publication number
KR102469995B1
KR102469995B1 KR1020187031861A KR20187031861A KR102469995B1 KR 102469995 B1 KR102469995 B1 KR 102469995B1 KR 1020187031861 A KR1020187031861 A KR 1020187031861A KR 20187031861 A KR20187031861 A KR 20187031861A KR 102469995 B1 KR102469995 B1 KR 102469995B1
Authority
KR
South Korea
Prior art keywords
formula
independently selected
sulfonyl
optionally substituted
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187031861A
Other languages
English (en)
Korean (ko)
Other versions
KR20190015215A (ko
Inventor
로버트 제이. 알텐바흐
앤드류 보그단
히주반니 페트루 디우니수 코티
말론 디. 코워트
스테펜 엔 그레스즐러
한스 켈터만스
필립 알. 킴
데 플라스 스티븐 에미엘 반
쉬에칭 왕
Original Assignee
애브비 에스.에이.알.엘.
갈라파고스 엔.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 애브비 에스.에이.알.엘., 갈라파고스 엔.브이. filed Critical 애브비 에스.에이.알.엘.
Priority to KR1020227040379A priority Critical patent/KR102719916B1/ko
Publication of KR20190015215A publication Critical patent/KR20190015215A/ko
Application granted granted Critical
Publication of KR102469995B1 publication Critical patent/KR102469995B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020187031861A 2016-06-03 2017-05-24 헤테로아릴 치환된 피리딘 및 사용 방법 Active KR102469995B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020227040379A KR102719916B1 (ko) 2016-06-03 2017-05-24 헤테로아릴 치환된 피리딘 및 사용 방법

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662345315P 2016-06-03 2016-06-03
US62/345,315 2016-06-03
PCT/IB2017/053068 WO2017208115A1 (en) 2016-06-03 2017-05-24 Heteroaryl substituted pyridines and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020227040379A Division KR102719916B1 (ko) 2016-06-03 2017-05-24 헤테로아릴 치환된 피리딘 및 사용 방법

Publications (2)

Publication Number Publication Date
KR20190015215A KR20190015215A (ko) 2019-02-13
KR102469995B1 true KR102469995B1 (ko) 2022-11-24

Family

ID=59014678

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020187031861A Active KR102469995B1 (ko) 2016-06-03 2017-05-24 헤테로아릴 치환된 피리딘 및 사용 방법
KR1020227040379A Active KR102719916B1 (ko) 2016-06-03 2017-05-24 헤테로아릴 치환된 피리딘 및 사용 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020227040379A Active KR102719916B1 (ko) 2016-06-03 2017-05-24 헤테로아릴 치환된 피리딘 및 사용 방법

Country Status (35)

Country Link
US (2) US10138227B2 (https=)
EP (1) EP3464282B1 (https=)
JP (3) JP6968094B2 (https=)
KR (2) KR102469995B1 (https=)
CN (2) CN114671864B (https=)
AR (2) AR108672A1 (https=)
AU (3) AU2017273215B2 (https=)
CA (1) CA3022216A1 (https=)
CL (1) CL2018003323A1 (https=)
CO (1) CO2018012171A2 (https=)
CR (1) CR20180547A (https=)
CY (1) CY1124031T1 (https=)
DK (1) DK3464282T3 (https=)
DO (1) DOP2018000257A (https=)
EC (1) ECSP18094790A (https=)
ES (1) ES2806873T3 (https=)
HR (1) HRP20201068T1 (https=)
HU (1) HUE050248T2 (https=)
IL (3) IL288243B2 (https=)
LT (1) LT3464282T (https=)
MX (2) MX385054B (https=)
MY (1) MY199604A (https=)
PE (1) PE20190511A1 (https=)
PH (1) PH12018502534B1 (https=)
PL (1) PL3464282T3 (https=)
PT (1) PT3464282T (https=)
RS (1) RS60574B1 (https=)
RU (2) RU2756743C2 (https=)
SG (1) SG11201808842VA (https=)
SI (1) SI3464282T1 (https=)
SM (1) SMT202000394T1 (https=)
TW (4) TWI849782B (https=)
UY (2) UY40612A (https=)
WO (1) WO2017208115A1 (https=)
ZA (1) ZA201808423B (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100921397B1 (ko) * 2009-02-09 2009-10-14 (주)오엠티 인쇄회로기판의 세척장비 및 이를 이용한 세척방법
MA41051B1 (fr) 2014-10-06 2020-11-30 Vertex Pharma Modulateurs du régulateur de conductance transmembranaire de la mucoviscidose
US10138227B2 (en) * 2016-06-03 2018-11-27 Abbvie S.Á.R.L. Heteroaryl substituted pyridines and methods of use
CN109803962B (zh) 2016-09-30 2022-04-29 弗特克斯药品有限公司 囊性纤维化跨膜传导调控蛋白的调节剂、以及药物组合物
MD3551622T2 (ro) 2016-12-09 2021-03-31 Vertex Pharma Modulator al regulatorului conductanței transmembranare în fibroză chistică, compoziții farmaceutice, metode de tratament și procedeu pentru fabricarea modulatorului
EP3558982A1 (en) 2016-12-20 2019-10-30 AbbVie S.À.R.L. Deuterated cftr modulators and methods of use
TW201831471A (zh) 2017-02-24 2018-09-01 盧森堡商艾伯維公司 囊腫纖化症跨膜傳導調節蛋白的調節劑及其使用方法
US11253509B2 (en) 2017-06-08 2022-02-22 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
MA49631A (fr) 2017-07-17 2020-05-27 Vertex Pharma Méthodes de traitement de la fibrose kystique
JP7121794B2 (ja) 2017-08-02 2022-08-18 バーテックス ファーマシューティカルズ インコーポレイテッド ピロリジン化合物を調製するためのプロセス
US10988454B2 (en) 2017-09-14 2021-04-27 Abbvie Overseas S.À.R.L. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
WO2019079760A1 (en) 2017-10-19 2019-04-25 Vertex Pharmaceuticals Incorporated CRYSTALLINE FORMS AND COMPOSITIONS OF CFTR MODULATORS
EP3720849A2 (en) 2017-12-08 2020-10-14 Vertex Pharmaceuticals Incorporated Processes for making modulators of cystic fibrosis transmembrane conductance regulator
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
JP7214743B2 (ja) 2018-02-15 2023-01-30 バーテックス ファーマシューティカルズ インコーポレイテッド 嚢胞性線維症膜コンダクタンス制御因子のモジュレーターとしての大環状分子、それらの医薬組成物、嚢胞性線維症の治療におけるそれらの使用、及びそれらの製造方法
US10710994B2 (en) * 2018-03-19 2020-07-14 Genentech, Inc. Oxadiazole transient receptor potential channel inhibitors
WO2019193062A1 (en) 2018-04-03 2019-10-10 Abbvie S.Á.R.L Substituted pyrrolidines and their use
EP3774825A1 (en) 2018-04-13 2021-02-17 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
IT201900000687A1 (it) 2019-01-16 2020-07-16 Fondazione St Italiano Tecnologia Composti e composizioni per il trattamento della fibrosi cistica
UY38630A (es) 2019-04-03 2020-10-30 Vertex Pharma Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quística
US11345691B2 (en) 2019-06-03 2022-05-31 AbbVie Global Enterprises Ltd. Prodrug modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
WO2021011327A1 (en) 2019-07-12 2021-01-21 Orphomed, Inc. Compound for treating cystic fibrosis
TWI899097B (zh) 2019-08-14 2025-10-01 美商維泰克斯製藥公司 製備cftr調節劑之方法
TWI867024B (zh) 2019-08-14 2024-12-21 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白之調節劑
WO2021030552A1 (en) 2019-08-14 2021-02-18 Vertex Pharmaceuticals Incorporated Crystalline forms of cftr modulators
MX2022005809A (es) * 2019-11-12 2022-06-08 Genzyme Corp Heteroarilaminosulfonamidas de 5 miembros para tratar afecciones mediadas por una actividad deficiente del regulador de la conductancia a nivel transmembranario de la fibrosis quistica (cftr).
EP4058434A1 (en) 2019-11-12 2022-09-21 Genzyme Corporation 6-membered heteroarylaminosulfonamides for treating diseases and conditions mediated by deficient cftr activity
IL300413A (en) 2020-08-13 2023-04-01 Vertex Pharma Crystal forms of CFTR modulators
WO2022040447A2 (en) 2020-08-20 2022-02-24 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating respiratory diseases characterized by mucus hypersecretion
KR20230118123A (ko) 2020-12-10 2023-08-10 버텍스 파마슈티칼스 인코포레이티드 낭성 섬유증 치료 방법
US20220213041A1 (en) 2021-01-06 2022-07-07 AbbVie Global Enterprises Ltd. Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use
EP4274828A1 (en) 2021-01-06 2023-11-15 AbbVie Global Enterprises Ltd. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
AU2022331725A1 (en) 2021-08-19 2024-03-07 Syngenta Crop Protection Ag Method for controlling diamide resistant pests & compounds therefor
WO2024056798A1 (en) 2022-09-15 2024-03-21 Idorsia Pharmaceuticals Ltd Macrocyclic cftr modulators
CA3267788A1 (en) 2022-09-15 2024-03-21 Idorsia Pharmaceuticals Ltd COMBINATION OF MACROCYCLIC CFTR MODULATORS WITH CFTR CORRECTORS AND/OR CFTR POTENTIALIZERS
CN116813569B (zh) * 2023-07-10 2024-07-02 衡阳市中心医院 一种抗癌药中间体的制备方法和抗癌药的制备方法
WO2025186214A1 (en) 2024-03-05 2025-09-12 Idorsia Pharmaceuticals Ltd Macrocyclic cftr modulators

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013038386A1 (en) 2011-09-16 2013-03-21 Novartis Ag Heterocyclic compounds for the treatment of cystic fibrosis
WO2016193812A1 (en) 2015-06-02 2016-12-08 Abbvie S.A.R.L. Substituted pyridines and method of use

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1740532A4 (en) * 2004-03-30 2009-06-10 Univ California CFTR INHIBITOR COMPOUNDS CONTAINING HYDRAZIDS AND USES THEREOF
CA2569402A1 (en) 2004-06-04 2005-12-22 The Regents Of The University Of California Compounds having activity in increasing ion transport by mutant-cftr and uses thereof
RS56037B1 (sr) 2004-06-24 2017-09-29 Vertex Pharma Modulatori atp-vezujućih kasetnih transportera
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
EP2142498A2 (en) * 2007-04-02 2010-01-13 Institute for Oneworld Health Cftr inhibitor compounds and uses thereof
JP5686596B2 (ja) 2007-05-25 2015-03-18 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 嚢胞性線維症膜貫通コンダクタンス制御因子の調節因子
MX2010006421A (es) 2007-12-10 2010-06-25 Novartis Ag Compuestos organicos.
JP5637859B2 (ja) 2007-12-13 2014-12-10 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 嚢胞性線維症膜コンダクタンスレギュレーターのモジュレーター
CN102224141B (zh) 2008-10-23 2014-10-08 沃泰克斯药物股份有限公司 N-(4-(7-氮杂双环[2.2.1]庚-7-基)-2-(三氟甲基)苯基)-4-氧代-5-(三氟甲基)-1,4-二氢喹啉-3-甲酰胺的固体形式
EP2349263B1 (en) * 2008-10-23 2014-04-23 Vertex Pharmaceuticals Inc. Modulators of cystic fibrosis transmembrane conductance regulator
EP2382197B1 (en) 2008-12-30 2016-10-05 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2011008931A2 (en) * 2009-07-15 2011-01-20 Cystic Fibrosis Foundation Therapeutics, Inc. Arylpyrimidine compounds and combination therapy comprising same for treating cystic fibrosis & related disorders
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
KR101886459B1 (ko) 2010-10-08 2018-08-07 니발리스 테라퓨틱스, 인코포레이티드 S-나이트로소글루타티온 리덕타제 억제제로서의 신규한 치환된 퀴놀린 화합물
WO2012154880A1 (en) * 2011-05-09 2012-11-15 Proteostasis Therapeutics, Inc. Proteostasis regulators for treating cystic fibrosis and other protein misfolding diseases
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
US9056867B2 (en) * 2011-09-16 2015-06-16 Novartis Ag N-substituted heterocyclyl carboxamides
AU2012312520A1 (en) 2011-09-20 2014-05-08 The University Of North Carolina At Chapel Hill Regulation of sodium channels by PLUNC proteins
WO2014180562A1 (en) 2013-05-07 2014-11-13 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis
PT3030568T (pt) 2013-08-08 2018-12-24 Galapagos Nv Tieno[2,3-c]piranos como moduladores de cftr
US9745292B2 (en) 2014-03-13 2017-08-29 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing CFTR activity
WO2015138909A1 (en) 2014-03-13 2015-09-17 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
MX2017005663A (es) 2014-10-31 2018-03-01 Abbvie Sarl Tetrahidropiranos sustituidos y metodo de uso.
DK3212189T3 (da) 2014-10-31 2020-10-26 Abbvie Overseas Sarl Substituerede chromaner og fremgangsmåde til anvendelse deraf
EP3277647A1 (en) * 2015-03-31 2018-02-07 Vertex Pharmaceuticals (Europe) Limited Deuterated vx-661
US9840513B2 (en) 2015-07-16 2017-12-12 Abbvie S.Á.R.L. Substituted tricyclics and method of use
TW201735769A (zh) 2015-10-09 2017-10-16 盧森堡商艾伯維公司 經取代之吡唑并［３，４－ｂ］吡啶－６－羧酸及使用方法
BR112018007161B1 (pt) 2015-10-09 2024-01-16 Galapagos Nv COMPOSTOS PIRAZOLO[3,4-b]PIRIDIN-6-CARBOXAMIDA N-SULFONILADA, COMPOSIÇÃO FARMACÊUTICA CONTENDO OS DITOS COMPOSTOS E USOS DOS MESMOS PARA TRATAR FIBROSE CÍSTICA
AU2017256172A1 (en) 2016-04-26 2018-09-06 AbbVie S.à.r.l. Modulators of cystic fibrosis transmembrane conductance regulator protein
US10138227B2 (en) 2016-06-03 2018-11-27 Abbvie S.Á.R.L. Heteroaryl substituted pyridines and methods of use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013038386A1 (en) 2011-09-16 2013-03-21 Novartis Ag Heterocyclic compounds for the treatment of cystic fibrosis
WO2016193812A1 (en) 2015-06-02 2016-12-08 Abbvie S.A.R.L. Substituted pyridines and method of use

Also Published As

Publication number Publication date
JP7392211B2 (ja) 2023-12-06
PE20190511A1 (es) 2019-04-10
IL262415A (en) 2018-12-31
TWI849782B (zh) 2024-07-21
UY40612A (es) 2024-02-15
AU2021282409A1 (en) 2021-12-23
CR20180547A (es) 2019-10-30
HRP20201068T1 (hr) 2020-11-13
JP2022009448A (ja) 2022-01-14
PH12018502534B1 (en) 2020-09-23
WO2017208115A1 (en) 2017-12-07
BR112018074815A2 (pt) 2019-03-19
PT3464282T (pt) 2020-07-17
CN109311864A (zh) 2019-02-05
AR108672A1 (es) 2018-09-12
AU2024202468A1 (en) 2024-05-02
JP2019517455A (ja) 2019-06-24
IL288243B2 (en) 2023-11-01
AR124916A2 (es) 2023-05-17
TW202329959A (zh) 2023-08-01
US10604515B2 (en) 2020-03-31
AU2017273215A1 (en) 2018-10-25
RU2018138707A (ru) 2020-07-14
IL262415B (en) 2021-12-01
CO2018012171A2 (es) 2018-11-30
NZ747222A (en) 2025-06-27
TW202515560A (zh) 2025-04-16
KR20220162806A (ko) 2022-12-08
JP7622122B2 (ja) 2025-01-27
HUE050248T2 (hu) 2020-12-28
RU2756743C2 (ru) 2021-10-05
DK3464282T3 (da) 2020-07-27
US20170349576A1 (en) 2017-12-07
CY1124031T1 (el) 2022-03-24
RS60574B1 (sr) 2020-08-31
ES2806873T3 (es) 2021-02-18
TWI752961B (zh) 2022-01-21
LT3464282T (lt) 2020-09-10
MX385054B (es) 2025-03-14
MY199604A (en) 2023-11-08
TWI797926B (zh) 2023-04-01
CL2018003323A1 (es) 2019-03-22
MX2021009322A (es) 2021-09-08
MX2018014758A (es) 2019-04-29
RU2021127810A (ru) 2021-10-25
UY37272A (es) 2018-01-02
CA3022216A1 (en) 2017-12-07
SG11201808842VA (en) 2018-11-29
IL303196B2 (en) 2025-04-01
KR102719916B1 (ko) 2024-10-23
IL288243A (en) 2022-01-01
ZA201808423B (en) 2019-08-28
JP6968094B2 (ja) 2021-11-17
IL303196B1 (en) 2024-12-01
DOP2018000257A (es) 2018-12-31
RU2018138707A3 (https=) 2020-08-24
ECSP18094790A (es) 2019-01-31
KR20190015215A (ko) 2019-02-13
US20190055229A1 (en) 2019-02-21
CN114671864A (zh) 2022-06-28
PH12018502534A1 (en) 2019-10-21
TW202214614A (zh) 2022-04-16
SI3464282T1 (sl) 2020-12-31
CN114671864B (zh) 2025-04-08
JP2023172889A (ja) 2023-12-06
AU2017273215B2 (en) 2021-09-09
CN109311864B (zh) 2022-05-10
EP3464282A1 (en) 2019-04-10
IL288243B1 (en) 2023-07-01
SMT202000394T1 (it) 2020-09-10
TW201802085A (zh) 2018-01-16
NZ788542A (en) 2025-06-27
PL3464282T3 (pl) 2020-12-14
US10138227B2 (en) 2018-11-27
EP3464282B1 (en) 2020-04-22
IL303196A (en) 2023-07-01
AU2021282409B2 (en) 2024-01-18

Similar Documents

Publication Publication Date Title
KR102469995B1 (ko) 헤테로아릴 치환된 피리딘 및 사용 방법
US10047051B2 (en) Substituted pyridines and method of use
HK40006841B (en) Heteroaryl substituted pyridines and methods of use
HK40006841A (en) Heteroaryl substituted pyridines and methods of use
BR122024019066A2 (pt) Composto de piridina substituída com heteroarila, composições farmacêuticas que compreendem o mesmo e usos do mesmo para tratar fibrose cística
BR112018074815B1 (pt) Composto de piridina substituída com heteroarila
BR122024019066B1 (pt) Composto de piridina substituída com heteroarila, composições farmacêuticas que compreendem o mesmo e usos do mesmo para tratar fibrose cística

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 4